Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA

被引:52
作者
Hill, Lucas G. [1 ]
Loera, Lindsey J. [1 ]
Evoy, Kirk E. [1 ]
Renfro, Mandy L. [1 ]
Torrez, Sorina B. [1 ]
Zagorski, Claire M. [1 ]
Perez, Joshua C. [1 ]
Jones, Shaun M. [2 ]
Reveles, Kelly R. [1 ]
机构
[1] Univ Texas Austin, Coll Pharm, 2409 Univ Ave,A1910,PHR 2-222G, Austin, TX 78712 USA
[2] Univ Texas Austin, Dept Psychiat & Behav Sci, Austin, TX 78712 USA
关键词
Buprenorphine; naloxone; opioid substitution treatment; opioid‐ related disorders; pharmacists; pharmacy; OVERDOSE MORTALITY; OPIOID OVERDOSE; ACCESS;
D O I
10.1111/add.15314
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background and Aims Patients with opioid use disorder (OUD) must be able to obtain prescribed buprenorphine/naloxone films (BUP/NX) and naloxone nasal spray (NNS) from a pharmacy promptly to reduce risk for a recurrence of use and subsequent morbidity and mortality. Telephone audits have identified concerning gaps in availability of NNS within US pharmacies, but the availability of BUP/NX has not been rigorously evaluated. This study estimated the availability of BUP/NX and NNS in the US state of Texas and compared availability by pharmacy type and metropolitan status. Design A cross-sectional telephone audit with a secret shopper approach conducted from 18 May 2020 to 7 June 2020. Setting and Participants A random sample of 800 of 5078 (16%) community pharmacies licensed with the Texas State Board of Pharmacy. Measurements Primary outcomes included availability of a 1-week supply of generic BUP/NX 8/2 mg films and a single unit of NNS 4 mg, overall and by pharmacy type. Secondary outcomes included willingness and estimated time-frame to order BUP/NX if unavailable. Findings Data from 704 pharmacies (471 chain, 233 independent) were included for analyses. Of these, 34.1% of pharmacies (45.0% of chains versus 12.0% of independents, P < 0.0001) were willing and able to dispense a 1-week supply of generic BUP/NX and a single unit of NNS. BUP/NX alone was available in 42.2% of pharmacies (52.4% of chains versus 21.5% of independents, P < 0.0001). NNS alone was available in 60.1% of pharmacies (77.9% of chains versus 24.0% of independents, P < 0.0001). Of the 397 pharmacies with generic BUP/NX unavailable, 62.2% of pharmacies (73.9% of chains versus 48.0% of independents, P < 0.0001) indicated willingness to order. Conclusions Most pharmacies in Texas do not appear to be willing and able to dispense prescribed buprenorphine/naloxone films and naloxone nasal spray to patients with opioid use disorder in a timely manner. Deficiencies in availability are markedly more pronounced in independent pharmacies compared with chain pharmacies.
引用
收藏
页码:1505 / 1511
页数:7
相关论文
共 32 条
[1]   Regional and temporal effects of naloxone access laws on opioid overdose mortality [J].
Cataife, Guido ;
Dong, Jing ;
Davis, Corey S. .
SUBSTANCE ABUSE, 2021, 42 (03) :329-338
[2]   When Prescribing Isn't Enough - Pharmacy-Level Barriers to Buprenorphine Access [J].
Cooper, Hannah L. F. ;
Cloud, David H. ;
Young, April M. ;
Freeman, Patricia R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (08) :703-705
[3]   Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States [J].
Davis, Corey S. ;
Carr, Derek H. .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 73 :42-48
[4]   Naloxone availability and dispensing in Indiana pharmacies 2 years after the implementation of a statewide standing order [J].
Eldridge, Lori Ann ;
Agley, Jon ;
Meyerson, Beth E. .
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2020, 60 (03) :470-474
[5]   Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas [J].
Evoy, Kirk E. ;
Hill, Lucas G. ;
Groff, Lindsey ;
Mazin, Lubna ;
Carlson, Christian C. ;
Reveles, Kelly R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (18) :1932-1937
[6]   Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder X the X Waiver [J].
Fiscella, Kevin ;
Wakeman, Sarah E. ;
Beletsky, Leo .
JAMA PSYCHIATRY, 2019, 76 (03) :229-230
[7]   The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints [J].
Gertner, Alex K. ;
Robertson, Allison G. ;
Jones, Hendree ;
Powell, Byron J. ;
Silberman, Pam ;
Domino, Marisa E. .
HEALTH SERVICES RESEARCH, 2020, 55 (03) :383-392
[8]   Naloxone Availability and Pharmacy Staff Knowledge of Standing Order for Naloxone in Pennsylvania Pharmacies [J].
Graves, Rachel L. ;
Andreyeva, Elena ;
Perrone, Jeanmarie ;
Shofer, Frances S. ;
Merchant, Raina M. ;
Meisel, Zachary F. .
JOURNAL OF ADDICTION MEDICINE, 2019, 13 (04) :272-278
[9]   Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017 [J].
Guadamuz, Jenny S. ;
Alexander, G. Caleb ;
Chaudhri, Tanya ;
Trotzky-Sirr, Rebecca ;
Qato, Dima M. .
JAMA NETWORK OPEN, 2019, 2 (06) :e195388
[10]   Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder [J].
Jones, Christopher M. ;
McCance-Katz, Elinore F. .
ADDICTION, 2019, 114 (03) :471-482